Table 1.
Baseline characteristics of all patients at the time of ibrutinib start (n = 209)
| Characteristic | Total | Standard initial dose (420 mg) | Reduced initial dose (<420 mg) | P‐value |
|---|---|---|---|---|
| N | 209 | 122 | 87 | |
| Median (range) age (y) | 69 (42‐94) | 67 (42‐94) | 72 (47‐90) | <.001 |
| Males | 148 (71%) | 82 (67%) | 66 (76%) | .18 |
| Rai stage | ||||
| 0 | 26 (13%) | 19 (16%) | 7 (9%) | .18 |
| I‐II | 62 (31%) | 39 (33%) | 23 (29%) | |
| III‐IV | 110 (56%) | 60 (51%) | 50 (62%) | |
| Missing | 11 | 4 | 7 | |
| Beta‐2 microglobulin (μg/mL) | ||||
| Median (range) | 4.0 (1.6‐28.2) | 4.0 (1.6‐11.4) | 4.7 (2.2‐28.2) | .16 |
| Missing | 113 | 58 | 55 | |
| LDH (U/L) | ||||
| Median (range) | 216 (109‐1178) | 216 (117‐1178) | 217 (109‐483) | .17 |
| Missing | 6 | 4 | 2 | |
| IGHV | ||||
| Mutated | 46 (26%) | 23 (22%) | 23 (31%) | .19 |
| Unmutated | 131 (74%) | 80 (78%) | 51 (69%) | |
| Missing | 32 | 19 | 13 | |
| FISH | ||||
| Standard risk (del13, +12, normal) | 113 (62%) | 64 (59%) | 49 (65%) | .41 |
| High risk (del11q, del17p) | 70 (38%) | 44 (41%) | 26 (35%) | |
| Missing | 26 | 14 | 12 | |
| TP53 disruption (including del17p and TP53 mutation) | ||||
| No | 151 (80%) | 84 (76%) | 67 (85%) | .15 |
| Yes | 38 (20%) | 26 (24%) | 12 (15%) | |
| Missing | 20 | 12 | 8 | |
| Number of prior CLL therapies | ||||
| 0 | 47 (22%) | 32 (26%) | 15 (17%) | .14 |
| 1‐2 | 88 (42%) | 45 (37%) | 43 (49%) | |
| ≥3 | 74 (35%) | 45 (37%) | 29 (33%) | |
Abbreviations: FISH, fluorescent in situ hybridization; IGHV, immunoglobulin heavy chain gene mutation status; LDH: lactate dehydrogenase.
Bold indicates P‐value < .05